Gammagard S/D IGIV is for intravenous (IV) infusion only and must be administered by a qualified healthcare professional. It is a freeze-dried powder that requires reconstitution before use.
Preparation and Handling:
- Reconstitution: Gammagard S/D is supplied as a freeze-dried powder (e.g., 5g or 10g vials) and must be reconstituted with sterile water for injection. The final concentration (e.g., 5% or 10%) depends on the amount of diluent added. Instructions for reconstitution are specific and must be followed carefully (e.g., using a transfer device, swirling gently, avoiding shaking).
- Visual Inspection: After reconstitution, the solution should be clear or slightly opalescent and colorless to pale yellow. Do not use if it is cloudy or contains particulate matter.
- Temperature: Allow the reconstituted solution to reach room temperature before administration.
- Use Promptly: Administer the reconstituted solution as soon as possible, ideally within 12 hours.
Administration:
- IV Infusion: Gammagard S/D is administered directly into a vein using an infusion pump.
- Infusion Rate: The infusion typically begins at a slow initial rate (e.g., 0.5 mL/kg/hour for a 5% solution) for the first 15-30 minutes. If tolerated, the rate can be gradually increased in increments, up to a maximum rate (e.g., 4 mL/kg/hour for a 5% solution, or up to 8 mL/kg/hour for a 10% solution depending on patient tolerance and risk factors). For patients at risk of renal dysfunction or thrombotic complications, slower rates are crucial.
- Monitoring: Vital signs (blood pressure, heart rate, temperature, respiratory rate) should be monitored closely throughout the entire infusion.
- Dedicated Line: Gammagard S/D should be infused via a separate IV line. Do not mix it with other IV medications or solutions.
- Filter: It should be given using a vented infusion set with a 15-micron filter.
The specific dose and infusion rate will be determined by the healthcare provider based on the patient’s condition, body weight, and tolerance.
Gammagard S/D IGIV works by providing functional human IgG antibodies, which are essential components of the immune system. Its mechanisms of action vary depending on the indication:
- Passive Immunization (for PI and CLL): In conditions like Primary Immunodeficiency and Chronic Lymphocytic Leukemia, where the body’s ability to produce sufficient functional antibodies is impaired, Gammagard S/D directly supplies a broad spectrum of IgG antibodies. These exogenous antibodies provide immediate passive immunity by binding to and neutralizing various pathogens (bacteria, viruses, toxins), thereby helping to prevent recurrent and severe infections.
- Immunomodulation (for ITP and Kawasaki Syndrome): In autoimmune and inflammatory conditions such as Idiopathic Thrombocytopenic Purpura and Kawasaki Syndrome, the high doses of IgG in Gammagard S/D are thought to exert complex immunomodulatory effects. While not fully understood, these include:
- Fc Receptor Blockade: The Fc (constant) region of the infused IgG molecules can saturate Fc receptors on immune cells (like macrophages), preventing them from binding to and destroying antibody-coated platelets (in ITP) or immune complexes (in Kawasaki Syndrome).
- Neutralization of Autoantibodies: The diverse antibody repertoire within Gammagard S/D may contain anti-idiotypic antibodies that can neutralize or interfere with pathogenic autoantibodies responsible for the autoimmune attack.
- Modulation of Cytokine Production: It can influence the balance of pro-inflammatory and anti-inflammatory cytokines, reducing overall inflammation.
- Complement System Inhibition: Gammagard S/D may interfere with the activation of the complement cascade, thereby reducing complement-mediated tissue damage.
- B and T Cell Regulation: It might modulate the activity of B and T lymphocytes, impacting the overall immune response.
Upon IV infusion, the IgG is rapidly distributed between plasma and extravascular fluid, reaching peak levels almost immediately. The half-life of IgG can vary significantly among individuals but averages around 37.7 days for Gammagard S/D.
Side effects of Gammagard S/D IGIV are generally common, ranging from mild to moderate, but serious reactions can occur. Most common side effects are infusion-related and often manageable.
Common Side Effects (often infusion-related):
- Headache
- Fever, chills (rigors)
- Flushing
- Nausea, vomiting
- Back pain, joint pain, muscle cramps
- Dizziness
- Fatigue
- Hypotension (low blood pressure) or Hypertension (high blood pressure)
- Chest discomfort
- Rash or hives
These reactions are often associated with the rate of infusion and can frequently be minimized by slowing down the infusion or by pre-medicating with antihistamines or acetaminophen.
Serious Side Effects (less common, but require immediate medical attention):
- Severe Hypersensitivity/Anaphylaxis: Rare but potentially life-threatening allergic reactions, including severe hives, swelling of the face, tongue, or throat, difficulty breathing, wheezing, sudden dizziness or fainting, and rapid heartbeat. This risk is higher in IgA-deficient patients with anti-IgA antibodies.
- Acute Renal Dysfunction/Failure: Can occur, particularly in predisposed patients. Symptoms may include decreased urine output, sudden weight gain, or swelling of the hands/feet.
- Thromboembolic Events (Blood Clots): These can include stroke, myocardial infarction (heart attack), deep vein thrombosis (DVT), and pulmonary embolism (PE). Symptoms include chest pain, shortness of breath, sudden numbness or weakness, or pain/swelling in an arm or leg.
- Aseptic Meningitis Syndrome (AMS): A non-infectious inflammation of the meninges, characterized by severe headache, stiff neck, fever, photophobia (light sensitivity), nausea, and vomiting. Usually occurs within hours to 2 days after infusion.
- Hemolysis: Destruction of red blood cells, which can lead to anemia. Signs include dark urine, yellowing of the skin or eyes, and unusual fatigue.
- Transfusion-Related Acute Lung Injury (TRALI): A severe, non-cardiogenic pulmonary edema that can cause acute respiratory distress.
- Hyperproteinemia, Increased Serum Viscosity, Pseudohyponatremia: These can occur and require careful monitoring to avoid inappropriate management, especially true vs. pseudohyponatremia.
Any new, severe, or worsening symptoms experienced after infusion should be promptly reported to a healthcare provider.
Gammagard S/D IGIV carries several important warnings and precautions that healthcare providers and patients must be aware of to ensure safe administration and minimize risks.
- Boxed Warning (Thrombosis, Renal Dysfunction, Acute Renal Failure): Like all immune globulin products, Gammagard S/D carries a boxed warning.
- Thrombosis (Blood Clots): Thrombotic events can occur. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of clots, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Ensure adequate hydration before administration and administer at the minimum dose and infusion rate practicable for at-risk patients.
- Renal Dysfunction and Acute Renal Failure: Renal dysfunction, acute renal failure, and death can occur, particularly in predisposed patients (those with pre-existing renal insufficiency, diabetes mellitus, age over 65, volume depletion, sepsis, paraproteinemia, or those receiving nephrotoxic drugs). Gammagard S/D is sucrose-free, which may reduce this risk compared to sucrose-containing products, but adequate hydration and monitoring of renal function are still critical.
- Hypersensitivity/Anaphylaxis: Gammagard S/D is contraindicated in individuals with a history of anaphylactic or severe systemic hypersensitivity reactions to human immune globulin. It is also contraindicated in IgA-deficient patients with antibodies to IgA due to the increased risk of severe anaphylaxis. If hypersensitivity occurs, stop the infusion immediately and initiate appropriate medical management.
- Aseptic Meningitis Syndrome (AMS): This can occur. Patients should be monitored for its signs and symptoms.
- Hemolysis: Gammagard S/D contains blood group antibodies, which may cause a positive direct antiglobulin test (Coombs’ test) and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia.
- Transfusion-Related Acute Lung Injury (TRALI): Monitor patients for pulmonary adverse reactions.
- Transmissible Infectious Agents: While the product undergoes stringent viral inactivation/removal steps (solvent/detergent treatment, fractionation), a theoretical risk of transmitting infectious agents (e.g., viruses, variant Creutzfeldt-Jakob disease [vCJD]) cannot be completely eliminated.
- Interference with Live Virus Vaccines: Antibodies can interfere with the immune response to live attenuated virus vaccines.
- Interference with Laboratory Tests: Passively transferred antibodies can lead to false-positive serological tests or interfere with certain assays.
- Hyperproteinemia and Increased Serum Viscosity: These can occur and should be monitored, especially in patients with pre-existing hyperviscosity conditions.
- Pseudohyponatremia: A decrease in serum sodium can occur due to the high protein content, but this is a false reading (pseudohyponatremia) and should be distinguished from true hyponatremia to avoid inappropriate fluid management.
Patients and caregivers should be educated on the signs and symptoms of these serious adverse events and instructed to seek immediate medical attention if they occur.
Gammagard S/D, like other immune globulin products, can interact with other medications, primarily affecting vaccine efficacy and potentially increasing the risk of adverse events with certain drugs.
- Live Virus Vaccines: The antibodies contained in Gammagard S/D can interfere with the immune response to live attenuated virus vaccines (e.g., Measles, Mumps, Rubella [MMR], Varicella [chickenpox], oral Poliovirus vaccine). It is generally recommended to defer live virus vaccinations for at least 6 months, and up to 11 months after administration of Gammagard S/D. Patients should always consult their healthcare provider regarding vaccination schedules.
- Nephrotoxic Drugs: Concomitant use with other medications known to be toxic to the kidneys (nephrotoxic drugs) may increase the risk of acute kidney injury. Examples include certain antibiotics (e.g., aminoglycosides) or diuretics. Close monitoring of renal function is advised when such drugs are co-administered.
- Interference with Laboratory Tests: The passive transfer of antibodies from Gammagard S/D can lead to false-positive serological tests (e.g., for certain viral infections) or interfere with specific assays, such as blood group antibody testing (Coombs’ test), potentially leading to misinterpretations.
- Maltose/Sucrose-containing IVIG products: Gammagard S/D does not contain sucrose. However, some other IVIG products do. If a patient is on an IVIG product containing maltose, it can lead to false high blood glucose readings when using certain glucose monitoring systems, potentially resulting in inappropriate insulin administration. This is not a direct interaction with Gammagard S/D itself, but a crucial consideration if switching between IVIG products.
Patients should inform their healthcare provider about all medications, including prescription, over-the-counter, herbal remedies, and supplements, to assess potential interactions.
The dosage of Gammagard S/D IGIV is highly individualized based on the patient’s condition, body weight, and clinical response. It is administered intravenously.
- Primary Immunodeficiency (PI):
- Dose: Typically 300 to 600 mg/kg (0.3 to 0.6 g/kg) body weight, infused every 3 to 4 weeks.
- Adjustment: Dosage and frequency are adjusted based on the patient’s clinical response (e.g., reduction in infection rate) and to achieve desired IgG trough serum levels (often aiming for trough levels above 500-800 mg/dL).
- B-cell Chronic Lymphocytic Leukemia (CLL):
- Dose: 400 mg/kg body weight, infused every 3 to 4 weeks, for patients with hypogammaglobulinemia and/or recurrent bacterial infections.
- Chronic Idiopathic Thrombocytopenic Purpura (ITP):
- Dose: 1 g/kg (1000 mg/kg) as a single dose. Up to three separate doses may be given on alternate days if required, depending on platelet count and clinical response.
- Kawasaki Syndrome (Pediatric Patients):
- Dose: Either a single 1 g/kg dose or a dose of 400 mg/kg for four consecutive days. Administration should begin within 7 days of the onset of fever, and it is given concomitantly with appropriate aspirin therapy (80-100 mg/kg/day in four divided doses).
Infusion Rate:
- Initial infusion rates are typically low (e.g., 0.5 mL/kg/hour for a 5% solution, or 0.5 mg/kg/min).
- If well tolerated, the rate may be gradually increased in step-wise increments.
- Maximum infusion rates vary but can reach up to 4 mL/kg/hour for a 5% solution or 8 mL/kg/hour for a 10% solution for patients with no history of adverse reactions and no significant risk factors for renal dysfunction or thrombotic complications.
- For patients at increased risk (e.g., elderly, renal impairment, cardiovascular disease, hyperviscosity), the infusion rate should be kept to the minimum practicable, often less than 2 mL/kg/hour for a 10% solution or 4 mL/kg/hour for a 5% solution.
Gammagard S/D IGIV is a prescription-only medication (POM). Its use is highly regulated due to its specialized nature, potential risks, and the need for careful patient management.
- Specialist Prescription: Gammagard S/D must be prescribed by a licensed healthcare professional with expertise in diagnosing and managing the specific conditions for which it is indicated. This typically includes immunologists, hematologists, and pediatric specialists.
- Confirmed Diagnosis: A clear and confirmed medical diagnosis for one of its approved indications (Primary Immunodeficiency, CLL with hypogammaglobulinemia/recurrent infections, chronic ITP, or Kawasaki Syndrome) is required.
- Medical Necessity and Prior Authorization: Due to its significant cost and specialized application, Gammagard S/D frequently requires prior authorization from insurance companies. This process usually involves submitting detailed clinical documentation to justify its medical necessity.
- Administration by Healthcare Professional: As an intravenous infusion, Gammagard S/D must be prepared and administered by trained healthcare professionals in a controlled medical setting (e.g., hospital, infusion center). It is not for home self-administration.
- Comprehensive Monitoring Plan: The prescribing physician is responsible for establishing and overseeing a thorough monitoring plan. This includes:
- Efficacy Monitoring: Regular assessment of clinical response (e.g., infection rates in PI, platelet counts in ITP, neurological status in Kawasaki Syndrome) and relevant laboratory parameters (e.g., IgG trough levels for PI patients).
- Safety Monitoring: Close monitoring of vital signs during infusion, and periodic laboratory tests to check kidney function (serum creatinine, BUN), complete blood counts, and to screen for potential adverse reactions like hemolysis or thrombosis.
- Patient Education: While administered by professionals, patients and their families should receive comprehensive education regarding the purpose of the treatment, potential side effects (especially serious ones), and when to seek immediate medical attention.
